XML 8 R2.htm IDEA: XBRL DOCUMENT v3.25.3
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Sep. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 293.1 $ 183.4
Accounts receivable, net 550.9 565.5
Inventories 1,196.6 1,067.8
Other current assets 310.0 236.5
Total current assets 2,350.6 2,053.2
Property, plant and equipment, net 746.7 669.3
Goodwill and intangible assets, net 2,468.8 2,419.8
Other long-term assets 868.8 664.4
Total assets 6,434.9 5,806.7
Current liabilities:    
Current portion of long-term debt and finance lease obligations 24.3 32.5
Accounts payable 184.4 234.1
Deferred revenue and customer advances 455.4 438.2
Other current liabilities 604.0 576.5
Total current liabilities 1,268.1 1,281.3
Long-term debt 1,984.2 2,061.8
Other long-term liabilities 690.2 648.4
Redeemable noncontrolling interests 42.9 18.1
Shareholders' equity:    
Common stock, par value $0.01; Authorized - 260,000,000 shares Issued - 182,170,700 shares (2024: 182,456,831); Outstanding - 151,391,821 shares (2024: 151,677,952) 1.8 1.8
Treasury stock, at cost Purchased - 30,979,610 shares (2024: 30,778,879) (1,247.2) (1,237.2)
Additional paid-in capital 1,404.3 713.4
Retained earnings 2,352.2 2,406.7
Accumulated other comprehensive loss, net of tax (79.2) (103.5)
Total shareholders' equity attributable to Bruker Corporation 2,431.9 1,781.2
Noncontrolling interests in consolidated subsidiaries 17.6 15.9
Total shareholders' equity 2,449.5 1,797.1
Total liabilities, redeemable noncontrolling interests and shareholders' equity 6,434.9 5,806.7
Series A Mandatory Convertible Preferred Stock    
Shareholders' equity:    
Preferred stock, par value $0.01; Authorized - 5,000,000 shares Series A 6.375% Mandatory Convertible; $250 per share liquidation preference or $692.6 million in the aggregate; Issued and outstanding - 2,760,000 shares (2024: nil) $ 0.0 $ 0.0